Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
199.4 EUR | -2.04% | +4.34% | -6.19% |
06-07 | The job report just threw a spanner in the works | |
06-07 | Mizuho Initiates Charles River Laboratories International With Neutral Rating, $235 Price Target | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With a 2024 P/E ratio at 27.15 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.19% | 11.06B | - | ||
+51.85% | 57.87B | B- | ||
+41.42% | 40.25B | A | ||
-5.25% | 39.94B | B | ||
-5.16% | 28.54B | C | ||
+12.79% | 26.4B | B- | ||
-20.18% | 19.33B | B | ||
+30.88% | 12.4B | C+ | ||
+0.61% | 12.23B | B+ | ||
+25.06% | 12.2B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CRL Stock
- RV6 Stock
- Ratings Charles River Laboratories International, Inc.